These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 19826195)
21. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573 [TBL] [Abstract][Full Text] [Related]
22. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Moser C; Lang SA; Stoeltzing O Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462 [TBL] [Abstract][Full Text] [Related]
23. Geldanamycin, a HSP90 inhibitor, attenuates the hypoxia-induced vascular endothelial growth factor expression in retinal pigment epithelium cells in vitro. Wu WC; Kao YH; Hu PS; Chen JH Exp Eye Res; 2007 Nov; 85(5):721-31. PubMed ID: 17870069 [TBL] [Abstract][Full Text] [Related]
24. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065 [TBL] [Abstract][Full Text] [Related]
27. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Nimmanapalli R; O'Bryan E; Bhalla K Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726 [TBL] [Abstract][Full Text] [Related]
28. Hsp90 functions to balance the phosphorylation state of Akt during C2C12 myoblast differentiation. Yun BG; Matts RL Cell Signal; 2005 Dec; 17(12):1477-85. PubMed ID: 15935620 [TBL] [Abstract][Full Text] [Related]
29. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. Williams CR; Tabios R; Linehan WM; Neckers L J Urol; 2007 Oct; 178(4 Pt 1):1528-32. PubMed ID: 17707057 [TBL] [Abstract][Full Text] [Related]
30. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904 [TBL] [Abstract][Full Text] [Related]
31. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors. Mayer P; Harjung A; Breinig M; Fischer L; Ehemann V; Malz M; Scherübl H; Britsch S; Werner J; Kern MA; Bläker H; Schirmacher P; Bergmann F Endocr Relat Cancer; 2012 Jun; 19(3):217-32. PubMed ID: 22194440 [TBL] [Abstract][Full Text] [Related]
32. Immune expression and inhibition of heat shock protein 90 in uveal melanoma. Faingold D; Marshall JC; Antecka E; Di Cesare S; Odashiro AN; Bakalian S; Fernandes BF; Burnier MN Clin Cancer Res; 2008 Feb; 14(3):847-55. PubMed ID: 18245548 [TBL] [Abstract][Full Text] [Related]
33. [Effect of HSP90 function inhibited on the telomerase and P53 mutant in breast cancer cells]. Li X; Deng HY Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 39(2):181-3. PubMed ID: 18630678 [TBL] [Abstract][Full Text] [Related]
34. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Demidenko ZN; Vivo C; Halicka HD; Li CJ; Bhalla K; Broude EV; Blagosklonny MV Cell Death Differ; 2006 Sep; 13(9):1434-41. PubMed ID: 16311509 [TBL] [Abstract][Full Text] [Related]
35. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378 [TBL] [Abstract][Full Text] [Related]
36. New non-quinone geldanamycin analogs from genetically engineered Streptomyces hygroscopicus. Wu CZ; Moon AN; Jang JH; Lee D; Kang SY; Park JT; Ahn JS; Hwang BY; Kim YH; Lee HS; Hong YS J Antibiot (Tokyo); 2011 Jun; 64(6):461-3. PubMed ID: 21448187 [No Abstract] [Full Text] [Related]
37. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells. Li YP; Chen JJ; Shen JJ; Cui J; Wu LZ; Wang Z; Li ZR Cancer Chemother Pharmacol; 2015 Apr; 75(4):773-82. PubMed ID: 25681003 [TBL] [Abstract][Full Text] [Related]
38. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells. Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408 [TBL] [Abstract][Full Text] [Related]
39. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation. Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406 [TBL] [Abstract][Full Text] [Related]
40. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Davenport EL; Zeisig A; Aronson LI; Moore HE; Hockley S; Gonzalez D; Smith EM; Powers MV; Sharp SY; Workman P; Morgan GJ; Davies FE Leukemia; 2010 Oct; 24(10):1804-7. PubMed ID: 20703255 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]